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Abstract
Rationale The influence of ovarian hormones on behaviour
is well accepted, and oestrogen replacement therapy has
proven to be beneficial in several cases of menopausal mood
disorders. However, there are also some adverse effects of
such a therapy, like anxiety and dysphoria. In fact, some
women feel better at low levels of oestrogen and worse
when levels fluctuate. Still, it is unclear which receptors
might mediate negative emotional effects.
Objectives The aim of this study was to identify which
oestrogen receptor(s) are capable of mediating negative
emotional effects and, therefore, may represent candidates
responsible for the adverse side effects observed in oestro-
gen replacement therapy.
Results We provide evidence from mouse behavioural tests
that oestrogen-induced anxiogenic-like effects might be me-
diated, at least in part, by the G protein-coupled receptor
GPR30. The short-term application of specific agonists
against the alpha and beta oestrogen receptors did not result
in marked behavioural changes. In contrast, the specific
stimulation of GPR30 in male and ovariectomized female
mice induced anxiogenic effects. The anxiogenic effects
induced by the specific GPR30 agonist G-1 were compara-
ble (and non-accumulative) to those observed after low
doses of the general oestrogen receptor agonist 17b-oestradiol
in male mice, thereby reflecting the behavioural changes
observed in intact female mice during early pro-oestrus.
Conclusions Our data suggest that GPR30 induces acute
anxiogenic effects of oestrogen in rodents. It is tempting to
speculate that a potential imbalance in the expression of the
anxiolytic beta oestrogen receptor and the anxiogenic
GPR30 may also be involved in the negative symptoms of
oestrogen replacement therapy in humans.
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Introduction
Mood disorders are one of the most common disorders in
developed countries. The overall prevalence of anxiety dis-
orders was estimated to be about 2% to 10%, potentially
reaching 20% in the elderly (Lindesay et al. 1989; Lehtinen
et al. 1990; Flint 1994). While gender differences in severe
mental health disorders, such as schizophrenia or bipolar
disorders, are hardly noticeable, women score markedly
higher in the prevalence of depression and anxiety disorders.
This difference manifests after puberty (for review, see
Hayward and Sanborn 2002), indicating the importance of
sexual hormones. Changes in mood throughout the menstrual
cycle display strong inter-individual differences, with a sub-
group of women experiencing severe premenstrual anxiety
symptoms (Chisholm et al. 1990).
In line with alterations in anxiety during the menstrual cycle
in human beings (Toufexis et al. 2006), alterations in anxiety-
related tests were also reported for female rodents (Frye et al.
2000; Marcondes et al. 2001; Morgan and Pfaff 2002). While
anxiety levels appeared to be lower during late pro-oestrus and
oestrus, indicators of increased anxiety were observed during
late dioestrus/early pro-oestrus, the time of rising oestrogen in
female mice and rats. It was suggested that these mood changes
might be due to the anxiolytic effects of larger amounts of
oestrogen, which are preceded by the anxiogenic effects of
fluctuations in oestrogen levels (Toufexis et al. 2006).
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Constantly increased oestrogen (E2) levels via E2 replace-
ment therapy can improve mood conditions in menopausal
women and younger women with low E2 levels. However,
not all individuals respond favourably to E2. Under certain
circumstances, women reported feeling even less anxiety
when E2 levels were low and/or stable, rather than rising
(Walf and Frye 2006). Women suffering from premenstrual
syndrome were frequently found in this group, which led to
the hypothesis of individual sex steroid sensitivity (for re-
view, see Backstrom et al. 2003).
Oestrogen exerts its effects through two classes of recep-
tors, the nuclear receptors alpha (ERα) and beta (ERβ) and
membrane-bound G-protein-coupled receptor(s), with the
orphan receptor GPR30 being the most prominent candi-
date. While the anxiolytic effects of oestrogen treatment are
mostly attributed to the nuclear receptor ERβ (Tetel and
Pfaff 2010), the neurobiochemical background of the anx-
iogenic effects of low and fluctuating levels of oestrogen
have only been marginally investigated so far.
The aim of this study was to identify which receptor(s)
displays anxiogenic properties. This/these receptor(s) might
represent candidates for being in imbalance with the anxiolytic
ERβ in women who suffer from premenstrual syndrome or
who respond negatively to oestrogen replacement therapy.
Thus, either antagonists to this/these receptor(s) or ERβ-




Commercial C57Bl/6 N mice (Charles River, Sulzfeld,
Germany) were either used directly or bred for a maximum
of three generations in our animal facility. Data obtained from
the purchased animals were indistinguishable from those bred
in our own facility. If bred and purchased animals were used
within one experiment, equal distribution between groups was
controlled. For breeding and maintenance, the mice were
group housed with free access to food and water. The temper-
ature was fixed at 23°C with 60% humidity and a 12 h light–
dark cycle (lights on 7 a.m. to 7 p.m.). Age and testing-
experience-matched intact and ovariectomized mice at 3 to
8 months of age were used in all experiments. The ovariecto-
my procedure was performed on mice at the age of 3 months
under anaesthesia initialized by ketamin and maintained by
sevoflouran. The mice received a single dose of 2 mg/kg
meloxicam for postsurgical analgesia. Testing started after
3 weeks of recovery. All procedures involving animals were
approved by the Austrian Animal Experimentation Ethics
Board in compliance with the European convention for the
protection of vertebrate animals used for experimental and
other scientific purposes, ETS no. 123. Every effort was taken
to minimize the number of animals used.
Determination of oestrous stage
The oestrous stage was identified from vaginal smears based
on the presence and proportion of round, nucleated epithelial
cells, needle-like cornified (or keratinized) cells or leukocytes
(Marcondes et al. 2002; Goldman et al. 2007). The smears
were double analysed, natively and after GIEMSA staining.
All animals were tested for normal cycling over a period of
2 weeks, ovariectomized animals were controlled for lack of
cycling for 1 week starting 2 weeks after surgery. Only ani-
mals with normal cycling behaviour (or total lack in case of
ovariectomized mice) were included into tests. After each
anxiety test, oestrous stage was controlled and animals were
sorted into three groups containing animals that were in met-
oestrus or early dioestrus (called the dioestrus group), late
dioestrus or early pro-oestrus (called the pro-oestrus group)
or oestrus (called the oestrus group). Late pro-oestrus usually
occurred in the afternoon. In line with our testing time (9 a.m.
to 1 p.m.), no animals in this stage were tested.
Behavioural testing
Unless stated otherwise, the mice were transferred to the
ante-room of the testing facility 24 h before the commence-
ment of experiments. The free access to food and water, the
climate and the light–dark cycle were kept constant. The
tests were performed between 9 a.m. and 1 p.m. All tests
were video monitored and evaluated by an experimenter
blinded to the pharmacological treatment of the animals.
All animals were controlled for abnormal behaviour, intact
reflexes and obvious health problems by giving them a
“physical exam” (Karl et al. 2003) 2 weeks before testing.
Tests were always performed following the sequence open
field test, elevated plus maze and light dark test with 7 test
free days between each test. The procedures for the open
field, elevated plus maze and light–dark choice tests were
performed as recently published (Wittmann et al. 2009) in
accordance with the recommendations of EMPRESS
(European Mouse Phenotyping Resource of Standardised
Screens; http://empress.har.mrc.ac.uk).
In short, the open field arenas had a size of 50×50 cm
and were illuminated to 150 lx. Mice were observed over
10 min, measuring time, distance travelled and number of
entries into three subfields: centre (central 16% of overall
area), border (8 cm along walls) and intermediate.
The light–dark test was performed in the same arenas
with a black box inserted, which covered 1/3 of the area.
Light was set to 400 lx and mice tested for 10 min measur-
ing time, distance travelled and number of entries into the
light compartment.
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The elevated plus maze test consisted of four arms, two
closed (20 cm walls) and two open arms, each 50×5 cm in
size elevated about 80 cm above ground. Exploratory activ-
ity on the open arms was tested over 5 min at 180 lx.
The forced swim test was performed in a single 15 min
trial at a water temperature of 25°C. Immobility, defined as
no activity for at least 2 s, was independently evaluated from
video clips for the interval from the second to the sixth
minute and for the final 4 min by two investigators blinded
to the genotype and/or treatment of the animals.
The tail suspension test was performed in a single 6-min trial.
Mice were elevated about 20 cm above a plate light to 150 lx.
Basal activity and circadian rhythm of intact and ovari-
ectomized mice was monitored in their home cages using
the Infra-Mot system (TSE, Bad Homburg, Germany).
Animals were observed for two dark–light cycles after an
initial accommodation phase of several hours.
Oestrogen receptor pharmacology
The general oestrogen receptor agonist β-oestradiol, the
specific oestrogen receptor α agonist 4,4′,4″-(4-propyl-
[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) (Stauffer et al.
2000) and the specific oestrogen receptor β agonist 2,3-bis
(4-hydroxyphenyl)-propionitrile (DPN) (Meyers et al. 2001)
were purchased from Tocris Cookson (Bristol, UK). The
specific agonist against the G-protein-coupled oestrogen
receptor (GPER=GPR30) 1-(4-(6-bromobenzo[1,3]dioxol-
5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-
ethanone (G-1) (Bologa et al. 2006) was purchased from
Calbiochem (VWR, Vienna, Austria). All drugs were dis-
solved in DMSO and subcutaneously injected 2 h or 2 and
24 h before testing in a total volume of 30 μl. The time
points were chosen to simulate the situation in late dioestrus/
early pro-oestrus. The dosages were chosen according to
recent studies on rodents (Lund et al. 2005). Assuming an
even distribution of β-oestradiol due to its chemical nature,
the doses we used yield concentrations of 0.1 to 1 μM and
therefore are on the lower end of the scale of doses used for in
vivo testing (Lund et al. 2005; Rocha et al. 2005; Kocic et al.
2010; Intapad et al. 2011). This is in line with our intention to
simulate the rising period of oestrogen and we assume mainly
oestrogen receptor mediated effects. The DMSO and agonist
treatments caused somemild signs of discomfort within the first
fewminutes after application, which weremost probably due to
the volume of about 30 μl being subcutaneously injected into
the inguinal region. In any case, a similar behaviour was
observed in all animals after the subcutaneous saline injec-
tion. No differences in ambulation in the open field were
observed between the animals injected with saline or
DMSO. No tissue irritations were observed in this region
when the mice were examined after the experiments.
Statistical analysis
Comparisons of more than two groups were performed using
one-way ANOVA followed by the Bonferroni or Dunnett
post-hoc tests, using Prism 5.0 (GraphPad Software Inc., La
Jolla, CA); P values of <0.05 were accepted as statistically




Anxiety-like behaviour was tested in the elevated plus maze,
light–dark choice tests and the open field test. Immediately
after the tests, the stage of the oestrous cycle was determined
from vaginal smears and the animals were grouped in rela-
tion to the oestrous stage for analysis (Fig. 1). The mice in
the late dioestrus/early pro-oestrus group displayed a signifi-
cant reduction in exploratory drive during the ovarian cycle as
compared to the met-oestrus/early dioestrus group. This was
reflected in all three parameters investigated: time spent on
(reduced by 73%), distance travelled on (reduced by 67%) and
number of entries (reduced by 38%) onto the open arms of the
elevated plus maze (Fig. 1a). In contrast, we observed no
changes in overall activity (12.4±1.3 (18); 11.3±1.3 (13);
10.8±1.2 (16) entries onto the closed arms in met-oestrus/
early dioestrus, late dioestrus/early pro-oestrus, and oestrus,
respectively). Decreased ambulation during the late dioestrus
and early pro-oestrus phases also became evident in the light–
dark choice test (Fig. 1b). The time spent in and the distance
travelled in the illuminated area were both reduced by 64%,
while the number of entries were only reduced during the late
dioestrous and early pro-oestrous phases of the ovarian cycle.
No behavioural differences throughout the oestrous cycle
were observed in the open field test (Fig. 1c).
Stress-related behaviour
Stress-related behaviour was tested in the forced swim and
tail suspension tests. Evaluation in respect to oestrous stage
revealed a 53% reduction in immobility in late dioestrus and
early pro-oestrus vs. met-oestrus and early dioestrus in the
early phase (second to sixth minute) of the forced swim test
(Fig. 1d), which most probably reflected increased anxiety
levels in this group of animals. In the late phase (the eleventh
to the fifteenth minute), no differences were observed between
the different stages of the oestrous cycle (Fig. 1e). No differ-
ences in stress coping abilities were observed throughout the
oestrous cycle in the tail suspension test (Fig. 1f).
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Ovariectomized female mice
The intact female mice displayed strong inter-individual dif-
ferences, which, at least partly, might have been due to the
fluctuations in oestrogen levels during the short phases of late
dioestrus and early pro-oestrus. The entire oestrous cycle only
lasts 5–7 days, with mice spending only a few hours in early
pro-oestrus. Therefore, we decided to switch to a hormonally
more stable system: ovariectomized females. The ovariectomy
procedure was performed in female mice at the age of 3months
to allow normal development of the oestrogen receptors.
Testing started after a recovery period of 3 weeks. During
the last week before testing, vaginal smears were taken daily
to ensure that the mice were no longer going through the
cycle. The ovariectomized mice did not show any abnormal
behaviour but they did display reduced motor activity in the
home cage. Intact female mice travelled 61.066±12.068 (7)
arbitrary activity counts over a 24 h period in their home cage.
Fig. 1 Anxiety-related parameters were evaluated in the elevated plus
maze (a), the light–dark choice test (b) and the open field test (c) in intact
female C57Bl/6 N mice at different stages of the oestrous cycle. In the
forced swim test, significant differences in immobility were only ob-
served during the initial phase of the test (second to sixth minute; d),
but not in the late phase (11th to 15th minute; e). No differences were
observed in the tail suspension test (f). Numbers in the columns indicate
the number of animals in the respective groups. *P<0.05, **P<0.01 vs.
di-group. dimet-oestrus + early dioestrus, pro late di- + early pro-oestrus,
oest oestrus, as assessed by vaginal smear analyses
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In contrast, ovariectomized mice only travelled 20.094±1.287
(4) arbitrary activity counts over a 24-h period, which was in
the range measured for male mice (Wittmann et al. 2009).
Effects of oestrogen treatment on anxiety-related behaviour
In order to investigate whether or not anxiogenic-like be-
haviour in early pro-oestrus can be mimicked by a general
oestrogen receptor agonist, 17β-oestradiol was applied 2 h
prior to testing in two different doses (0.025 and 0.25 mg/kg).
This early time point and the low doses of β-oestradiol were
chosen to simulate the early pro-oestrus phase of the cycle.
Treatment with the lower dose of β-oestradiol significantly
reduced the exploratory drive in the open field test (Fig. 2a).
Thus, the time spent in and the entries onto the centre were
reduced by 56%, and the distance travelled in the centre was
reduced by 48%. In contrast, little influence was observed on
behaviour in the elevated plus maze (Fig. 2b) and in the light–
dark choice tests (Fig. 2c). It is noteworthy that no reduction in
exploratory drive was observed after treatment with 0.25mgβ-
oestradiol/kg in the open field test, resulting in statistically
significant differences between low and highβ-oestradiol treat-
ments (Fig. 2a). In the elevated plus maze, ambulation on the
open arms appeared to be increased after treatment with
0.25 mg β-oestradiol/kg, also resulting in a statistically signif-
icant difference between low and high β-oestradiol treatments
(Fig. 2b). Thus, the anxiolytic and anxiogenic effects induced
by β-oestradiol are highly dependent on the dose applied and
the testing paradigm. This could be due to overlapping effects
of β-oestradiol mediated by different receptors. Therefore, we
decided to address this question by using specific oestrogen
receptor agonists.
Fig. 2 Ovariectomized female mice were tested 2 h after treatment
with 0.025 mg β-oestradiol/kg (Oest 0.025), 0.25 mg β-oestradiol/kg
(Oest 0.25) or DMSO. Anxiety-related parameters were evaluated in
the elevated plus maze (a) and the light–dark choice test (b), and the
open field test (c). Numbers in the columns indicate the number of
animals in the respective groups. *P<0.05, **P<0.01 vs. DMSO; #P≤
0.05 vs. est low
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Pharmacology of the effects of β-oestradiol
on anxiety-related behaviour
Agonists against the three presently known oestrogen recep-
tors (PPT against ERα, DPN against ERβ and G-1 against
GPR30; 1 mg/kg each) were given to ovariectomized female
mice 2 h before testing. Mice treated with PPT or DPN did
not differ from those treated with DMSO alone. A tendency
towards increased exploration in the light–dark test was
only observed after treatment with the ERβ agonist DPN.
In contrast, G-1, the GPR30 agonist, produced strong anx-
iogenic effects in the elevated plus maze and open field tests
(Fig. 3a, b) where, in the open field test, time spent in the
centre was reduced by 67%, distance travelled in the centre
was reduced by 47%, and the number of entries into the
centre was reduced by 59% after G-1 treatment. In line with
this, open arm time, distance and entries were reduced by
59%, 72%, and 45%, respectively. No significant alterations
were observed in the light–dark choice tests after G-1
treatment.
Intact male mice
Anxiogenic effects of both β-oestradiol and G-1 were also
observed in intact male mice, which displayed a markedly
reduced exploratory drive after treatment with β-oestradiol
or G-1 in all anxiety-related tests (Fig. 4). Beta-oestradiol
significantly reduced the explorative behaviour on the open
arms of the elevated plus maze for time and distance travelled
by 37% and 43%, respectively. Similarly, time and distance
travelled in the light–dark choice tests were decreased by 48%
each, after β-oestradiol application. Analysis of open field
exploration did not reveal significant differences after β-
oestradiol treatment. The application of G-1 induced strong
anxiogenic effects. Thus, open arm time, distance travelled
and entries onto the open arms were reduced by 60% and
Fig. 3 In order to overcome problems of potentially overlapping
actions of different receptors, ovariectomized female mice were tested
2 h after treatment with the ERα agonist PPT, the ERβ agonist DPN,
the GPER agonist G-1 and DMSO. Anxiety-related parameters were
evaluated in the elevated plus maze test (a), the light–dark choice test
(b), and the open field (c). Numbers in the columns indicate the
number of animals in the respective groups. *P<0.05, **P<0.01 vs.
DMSO; #P<0.05 vs. PPT
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64%, respectively. In the light–dark choice tests the explor-
atory parameters were decreased by 52%, 49%, and 48%
regarding time spent, distance travelled and entries into the
light area, respectively. Combined application of 1 mg/kg G-1
and 0.025 mg/kg oestradiol did not result in a further increase
in anxiogenic effects. The anxiogenic period in the oestrous
cycle lasts only a few hours and question was, whether the
anxiogenic receptors desensitize. To investigate this question,
we applied 1 mg/kg G-1 24 and 2 h before testing. Results
from these experiments did not differ markedly from those
obtained after 2 h treatment. Thusmice spent 10.7±3.54 s (15)
vs. 17.1±2.65 s (9) (p00.2170); and travelled 3.52±1.37 (15)
vs. 7.4±1.7% (9) (p00.0925); on the open arms (in 3.4±0.81
(15) vs. 2.3±0.88 entries (9); p00.3886) 2 h and 2+24 h after
treatment, respectively. In the light–dark test, 20.7±5.54 s (10)
vs. 12.2±5.22 s (9) (p00.2826); and travelled 2.0±0.52 (10)
vs. 1.1±0.47 m (9) (p00.2201); on the open arms (in 2.5±
0.50 (10) vs. 1.7±0.73 entries (9); p00.2638) 2 h and 2+24 h
after treatment, respectively. Exploration of the centre area of
the open field was also comparable between the two treatment
regimens (39.8±3.98 s (14) vs. 48.8±6.30 s (9); p00.2166;
9,4±0.91 (14) vs. 9.8±1.82% distance (9); p00.7845; in 25±
Fig. 4 Male mice are reported to display a similar pattern of oestrogen
receptor expression as females, but a constantly low level of oestrogen
expression. Therefore, we also analysed anxiety-related behaviour in
male mice 2 h after treatment with 0.025mgβ-oestradiol/kg or 1 mg/kg G-
1 (G-1 2 h). In addition, we included one group of animals that were treated
with G-1 and b-oestradiol 2h before testing (Oest + G1). Their behaviour
was analysed in the elevated plus maze (a), the light–dark choice (b), and
the open field tests (c). Numbers in the columns indicate the number of
animals in the respective groups. *P<0.05, **P<0.01 vs. DMSO
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2.13 (14) vs. 29±3.04 entries (9); p00.2791; 2 h and 2+24 h
after treatment, respectively). In line with intact females in the
late dioestrus and early pro-oestrus stages of the ovarian cycle
anxiety-like behaviour was clearly expressed in the elevated
plus maze (Figs. 1a and 4a) and light–dark choice tests
(Figs. 1b and 4b), but less so in the open field test (Figs. 1c
and 4c). The overall activity in these tests appeared to be
unchanged. The mice travelled 1.8±0.09 m (16); 1.6±
0.07 m (9); 1.6±0.12 m (14) and 1.9 ±0.09 m (9) after
treatment with DMSO, β-oestradiol and G-1 (2 and 2+24 h
before testing), respectively, in the elevated plus maze and 4.0±
0.12 m (14); 3.7±0.10 m (10); 4.8±0.98 m (14) and 4.6±
0.14 m (9) in the open field, respectively.
Discussion
During the menstrual cycle in humans and the oestrous cycle
in rodents the serum levels of the hormones oestradiol, pro-
gesterone and luteinizing hormone vary in a rhythmic pattern
(Goldman et al. 2007). Oestradiol rises in late dioestrus and
declines throughout late pro-oestrus, whereas progesterone
and luteinizing hormone start to rise in late pro-oestrus. As
we observed a reduced exploratory drive in intact female mice
during late dioestrus and early pro-oestrus, oestradiol repre-
sents the most probable candidate involved in this effect.
Indeed, the reduced exploratory drive could be mimicked in
ovariectomized female and intact male mice shortly after the
application of the low dose of β-oestradiol. The fact that a
higher dose of β-oestradiol induced contrary effects in ovari-
ectomized female mice suggests that distinct oestrogen recep-
tor populations may induce counteracting anxiogenic or
anxiolytic effects. This is in line with the assumption that
stable and high concentrations of oestrogen are anxiolytic,
whereas fluctuating and low levels of oestrogen often cause
anxiogenic effects (Toufexis et al. 2006). Anxiogenic effects
of oestrogen have been reported in female rats treated with
10 μg/kg oestradiol benzoate 3 h before testing (Mora et al.
1996). Anxiolytic effects of oestrogen were reported after
higher doses of β-oestradiol (of up to 250 μg/kg) over pro-
longed periods (i.e., several days). The ERβ was identified as
a primary candidate for mediating anxiolytic effects (Lund et
al. 2005), while ERα was apparently less important in emo-
tional control (for review, see Tetel and Pfaff 2010).
Functional investigations into GPR30, which was recently
proposed as an oestrogen receptor and therefore also named
GPER, are rare (for review, see Mizukami 2009), and no
information on the influence of GPR30 on anxiety is currently
available.
In order to overcome the potential problems of counter-
acting oestrogen receptor populations we applied specific
agonists against ERα, ERβ and GPR30. Agonists against
the nuclear oestrogen receptors did not significantly alter the
behaviour of mice at the dosage and time interval applied.
These receptors mainly mediate their effects through the
regulation of gene expression, while fast effects of oestrogen
are frequently thought to be mediated by at least one
membrane-bound receptor using alternative signalling path-
ways. In contrast to the nuclear receptor agonists, the
GPR30 agonist G-1 caused anxiogenic effects in ovariecto-
mized female WT mice. Anxiogenic effects of GPR30 stim-
ulation were also reproduced in male mice, which express
this receptor in a similar manner to female mice (Hazell et
al. 2009).
In the mouse, GPR30 is expressed in several nuclei
involved in emotional control, such as the paraventricular
hypothalamic nucleus, septal complex nuclei, hippocampal
nuclei and the supraoptic nucleus, for example (Hazell et al.
2009). Moreover, proposed functions of GPR30 such as the
release of Ca2+ from internal stores (for review, see Hazell et
al. 2009) may influence neuronal functions or facilitate the
release of neuropeptides. Of potential functional interest is a
recent study, which suggested that GPR30 is highly
expressed in neurons of the paraventricular hypothalamic
nucleus (PVN) of rats, where it is involved in the attenuation
of 5-HT1A receptor signalling (Xu et al. 2009). On the other
hand, there is an ongoing discussion about whether or not
GPR30 is indeed an oestrogen receptor; also, several con-
troversies on the functions of GPR30 exist (for review, see
Langer et al. 2010). Our data support the idea of GPR30 as a
mediator of oestrogen effects. Moreover, for the first time,
we provide evidence to show that the activation of GPR30
causes anxiogenic effects. These effects could be also ob-
served after prolonged stimulation of GPR30, suggesting
that the short-lived period of higher anxiety is not terminated
by desensitisation of GPR30, but the anxiolytic effects mediat-
ed through other receptors. This may also the neurobiological
background of the discrepancy between high doses of β-
oestradiol as a general oestrogen receptor agonist and the G-1
as a specific GPR30 agonist. Most probable candidates for
overlaying anxiogenic effects are genomic actions mediated
via ERβ (Lund et al. 2005).
Individual sex steroid sensitivity was hypothesized as
being an explanation for the severe mood changes during
the oestrous cycle and the aversive emotional side effects of
oestrogen replacement therapy in a subpopulation of women
(Backstrom et al. 2003). The anxiolytic effects mediated by
ERβ would be counteracted by a so far unknown mediator
of anxiogenic effects of oestrogen. Our data suggest that
GPR30 could represent this counteracting partner and an
imbalance between ERβ and GPR30 may be the neuro-
biochemical background of aversive emotional side effects
of oestrogen replacement therapy. Women from this group
often report that they feel better at low oestrogen levels,
which would make sense considering the approximately 10
times lower affinity of GPR30 to β-oestradiol than the
534 Psychopharmacology (2012) 221:527–535
nuclear receptors (Cornil et al. 2006). These women also
reported feeling worse under fluctuations of E2 levels,
which may reflect the faster transmission of effects by G-
protein coupled receptors compared to nuclear receptors,
which mostly mediate their effect through transcriptional
regulation. In any case, our data together with data pub-
lished on the anxiolytic effects of ERβ activation suggest
that the aversive effects of oestrogen therapies may be
overcome, at least in part, by avoiding the stimulation of
GPR30 during replacement therapy (i.e., through the devel-
opment of ERβ specific agonists).
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